Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-34.10M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.38 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -44.01% |
Return on Assets (Trailing 12 Months) | -38.58% |
Current Ratio (Most Recent Fiscal Quarter) | 11.92 |
Quick Ratio (Most Recent Fiscal Quarter) | 11.92 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $2.60 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
Earnings per Share (Most Recent Fiscal Year) | $-1.22 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.22 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 25.07M |
Free Float | 18.68M |
Market Capitalization | $24.86M |
Average Volume (Last 20 Days) | 0.09M |
Beta (Past 60 Months) | 0.17 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 25.50% |
Percentage Held By Institutions (Latest 13F Reports) | 10.50% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |